Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells
Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells
复制标题
DOI：
10.1111/j.1749-6632.2010.05779.x
复制
发表时间：
2010-01-01
期刊：
影响因子：
--
通讯作者：
Pantel, Klaus
中科院分区：
文献类型：
--
作者：
Riethdorf, Sabine;Pantel, Klaus
骨髓和其他器官中单个肿瘤细胞的早期播散、血液循环或归巢通常在初步诊断时无法检测到，即使是通过高分辨率成像技术。然而，超灵敏的方法现在可以检测到“隐匿”的肿瘤细胞。目前，许多研究人员都在关注外周血中的循环肿瘤细胞（CTC），一些出版物已经描述了CTC与转移性癌症患者和预后不良的关系。然而，有证据表明，目前使用的检测方法缺乏灵敏度或特异性来跟踪所有CTC，特别是那些已经失去特征性上皮特征的CTC。因此，这一领域的新发展极为令人感兴趣，将在此加以审查。此外，分子CTC分析将为接受全身治疗的患者的肿瘤细胞选择和耐药机制提供见解。这些信息可能有助于评估个体预后，对全身治疗的风险患者进行分层，并监测治疗效果。
Early dissemination, blood circulation, or homing of single tumor cells in bone marrow and other organs is usually undetectable at primary diagnosis, even by high resolution imaging technologies. However, ultrasensitive approaches now enable the detection of "occult" tumor cells. Many researchers are currently focusing on circulating tumor cells (CTC) in peripheral blood, and several publications have described associations of CTC in patients with metastatic cancer and worse prognosis. However, evidence has emerged that the currently used detection methods lack sensitivity or specificity to track all CTC, especially those that have lost characteristic epithelial features. Therefore, new developments in this field are of utmost interest and will be reviewed here. Moreover, molecular CTC analysis will provide insights into the selection of tumor cells and resistance mechanisms in patients undergoing systemic therapies. This information might support assessing individual prognosis, stratifying patients at risk to systemic therapies, and monitoring therapeutic efficacy.